Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Oncology·MeSH: Carcinoma in Situ
Prevalence
61.0 / 100K
Incidence
18.0 / 100K/yr
2 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Frequently asked questions
How many drugs are in development for Non-muscle Invasive Bladder Cancer With Carcinoma in Situ?
BioSniper tracks 2 drugs in development for Non-muscle Invasive Bladder Cancer With Carcinoma in Situ across 2 companies.
How many clinical trials target Non-muscle Invasive Bladder Cancer With Carcinoma in Situ?
There are 2 clinical trials targeting Non-muscle Invasive Bladder Cancer With Carcinoma in Situ tracked by BioSniper.
What is the prevalence of Non-muscle Invasive Bladder Cancer With Carcinoma in Situ?
The estimated prevalence of Non-muscle Invasive Bladder Cancer With Carcinoma in Situ is approximately 61.0 per 100,000 population.
Deep-dive into Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis